Jpmorgan Chase & CO Tarsus Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 27,973 shares of TARS stock, worth $1.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,973
Previous 129,184 78.35%
Holding current value
$1.95 Million
Previous $7.15 Million 79.92%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$41.29 - $56.94 $4.18 Million - $5.76 Million
-101,211 Reduced 78.35%
27,973 $1.44 Million
Q4 2024

Feb 12, 2025
SELL
$32.27 - $55.37 $10 Million - $17.2 Million
-310,983 Reduced 70.65%
129,184 $7.15 Million
Q3 2024

Dec 26, 2024
BUY
$21.54 - $34.6 $9.05 Million - $14.5 Million
420,057 Added 2088.8%
440,167 $14.5 Million
Q3 2024

Nov 08, 2024
BUY
$21.54 - $34.6 $9.05 Million - $14.5 Million
420,057 Added 2088.8%
440,167 $14.5 Million
Q2 2024

Dec 26, 2024
SELL
$25.17 - $38.73 $10.6 Million - $16.3 Million
-420,057 Reduced 95.43%
20,110 $546,000
Q2 2024

Aug 12, 2024
SELL
$25.17 - $38.73 $836,373 - $1.29 Million
-33,229 Reduced 62.3%
20,110 $546,000
Q1 2024

Dec 26, 2024
SELL
$19.61 - $39.22 $7.59 Million - $15.2 Million
-386,828 Reduced 87.88%
53,339 $1.94 Million
Q1 2024

May 10, 2024
BUY
$19.61 - $39.22 $544,550 - $1.09 Million
27,769 Added 108.6%
53,339 $1.94 Million
Q4 2023

Dec 26, 2024
SELL
$12.98 - $20.73 $5.38 Million - $8.59 Million
-414,597 Reduced 94.19%
25,570 $517,000
Q4 2023

Feb 12, 2024
BUY
$12.98 - $20.73 $45,014 - $71,891
3,468 Added 15.69%
25,570 $517,000
Q3 2023

Nov 14, 2023
BUY
$14.75 - $24.62 $42,819 - $71,471
2,903 Added 15.12%
22,102 $392,000
Q2 2023

Aug 11, 2023
BUY
$11.57 - $19.63 $48,941 - $83,034
4,230 Added 28.26%
19,199 $346,000
Q1 2023

May 18, 2023
BUY
$11.92 - $16.27 $167,809 - $229,049
14,078 Added 1580.02%
14,969 $188,000
Q1 2023

May 11, 2023
SELL
$11.92 - $16.27 $124,683 - $170,184
-10,460 Reduced 92.15%
891 $11,000
Q4 2022

Feb 13, 2023
BUY
$14.12 - $18.72 $18,483 - $24,504
1,309 Added 13.04%
11,351 $167,000
Q3 2022

Nov 14, 2022
BUY
$14.08 - $18.5 $4,913 - $6,456
349 Added 3.6%
10,042 $172,000
Q2 2022

Aug 11, 2022
BUY
$11.08 - $19.08 $63,588 - $109,500
5,739 Added 145.14%
9,693 $142,000
Q1 2022

May 11, 2022
SELL
$14.49 - $24.28 $2.47 Million - $4.15 Million
-170,782 Reduced 97.74%
3,954 $67,000
Q4 2021

Feb 10, 2022
BUY
$21.21 - $29.68 $3.64 Million - $5.09 Million
171,499 Added 5298.08%
174,736 $3.93 Million
Q3 2021

Nov 12, 2021
BUY
$21.45 - $29.22 $69,433 - $94,585
3,237 New
3,237 $70,000

Others Institutions Holding TARS

# of Institutions
215
Shares Held
46.5M
Call Options Held
7.8K
Put Options Held
0
View Full List

About Tarsus Pharmaceuticals, Inc.

TARS Quotes by TradingView
  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.86B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email